Brain transcriptome analysis of a CLN2 mouse model as a function of disease progression

被引:7
|
作者
Domowicz, Miriam S. [1 ]
Chan, Wen-Ching [2 ]
Claudio-Vazquez, Patricia [1 ]
Gonzalez, Tatiana [1 ]
Schwartz, Nancy B. [1 ,3 ]
机构
[1] Univ Chicago, Med Ctr, Dept Pediat, Biol Sci Div, 5841 S Maryland Ave,MC 5058, Chicago, IL 60637 USA
[2] Univ Chicago, Ctr Res Informat, Biol Sci Div, Chicago, IL 60637 USA
[3] Univ Chicago, Dept Biochem & Mol Biol, Biol Sci Div, Chicago, IL 60637 USA
关键词
Neuronal ceroid lipofuscinoses; Transcriptome; Lysosomal tripeptidyl peptidase 1; Pediatric neurodegeneration; Neuroinflammation; Choroid plexus; NEURONAL CEROID-LIPOFUSCINOSIS; TRIPEPTIDYL-PEPTIDASE-I; MATRIX METALLOPROTEINASE-12; CEREBROSPINAL-FLUID; GENE; CELLS; NEUROINFLAMMATION; PATHOLOGY; EXPRESSION; PROTEINS;
D O I
10.1186/s12974-021-02302-z
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Neuronal ceroid lipofuscinoses, (NCLs or Batten disease) are a group of inherited, early onset, fatal neurodegenerative diseases associated with mutations in 13 genes. All forms of the disease are characterized by lysosomal accumulation of fluorescent storage material, as well as profound neurodegeneration, but the relationship of the various genes' function to a single biological process is not obvious. In this study, we used a well-characterized mouse model of classical late infantile NCL (cLINCL) in which the tripeptidyl peptidase 1 (Tpp1) gene is disrupted by gene targeting, resulting in loss of detectable TPP1 activity and leading to progressive neurological phenotypes including ataxia, increased motor deficiency, and early death. Methods In order to identify genes and pathways that may contribute to progression of the neurodegenerative process, we analyzed forebrain/midbrain and cerebellar transcriptional differences at 1, 2, 3 and 4 months of age in control and TPP1-deficient mice by global RNA-sequencing. Results Progressive neurodegenerative inflammatory responses involving microglia, astrocytes and endothelial cells were observed, accompanied by activation of leukocyte extravasation signals and upregulation of nitric oxide production and reactive oxygen species. Several astrocytic (i.e., Gfap, C4b, Osmr, Serpina3n) and microglial (i.e., Ctss, Itgb2, Itgax, Lyz2) genes were identified as strong markers for assessing disease progression as they showed increased levels of expression in vivo over time. Furthermore, transient increased expression of choroid plexus genes was observed at 2 months in the lateral and fourth ventricle, highlighting an early role for the choroid plexus and cerebrospinal fluid in the disease pathology. Based on these gene expression changes, we concluded that neuroinflammation starts, for the most part, after 2 months in the Tpp1(-/-) brain and that activation of microglia and astrocytes occur more rapidly in cerebellum than in the rest of the brain; confirming increased severity of inflammation in this region. Conclusions These findings have led to a better understanding of cLINCL pathological onset and progression, which may aid in development of future therapeutic treatments for this disease.
引用
收藏
页数:18
相关论文
共 50 条
  • [21] Study of Intraventricular Cerliponase Alfa for CLN2 Disease
    Schulz, Angela
    Ajayi, Temitayo
    Specchio, Nicola
    de Los Reyes, Emily
    Gissen, Paul
    Ballon, Douglas
    Dyke, Jonathan P.
    Cahan, Heather
    Slasor, Peter
    Jacoby, David
    Kohlschutter, Alfried
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (20): : 1898 - 1907
  • [22] Enzyme Replacement Therapy Attenuates Disease Progression in a Canine Model of Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)
    Katz, Martin L.
    Coates, Joan R.
    Sibigtroth, Christine M.
    Taylor, Jacob D.
    Carpentier, Melissa
    Young, Whitney M.
    Wininger, Fred A.
    Kennedy, Derek
    Vuillemenot, Brian R.
    O'Neill, Charles A.
    JOURNAL OF NEUROSCIENCE RESEARCH, 2014, 92 (11) : 1591 - 1598
  • [23] Proteomic analysis of urine reveals potential markers for CLN2 Batten disease
    Heywood, Wendy E.
    Doykov, Ivan
    Sirka, Ernestas
    Clayton, Robert
    Csanyi, Barbara
    Cleary, Maureen
    Footitt, Emma
    Chakrapani, Anupam
    Abulhoul, Lara
    Grunewald, Stephanie
    Mole, Sara
    Gissen, Paul
    Mills, Kevin
    MOLECULAR GENETICS AND METABOLISM, 2016, 117 (02) : S57 - S57
  • [24] Intravitreal enzyme replacement therapy attenuates retinal disease progression in a canine model of neuronal ceroid lipofuscinosis type 2 (CLN2)
    Sinclair, John
    Whiting, Rebecca
    Robinson, Grace
    Bibi, Katherine
    Nguyen, Annailsa
    Cherukuri, Anu
    Henshaw, Joshua
    De Hart, Gregory
    Chandra, Sundeep
    O'Neill, Chuck
    Katz, Martin
    MOLECULAR GENETICS AND METABOLISM, 2018, 123 (02) : S132 - S132
  • [25] Intravitreal Enzyme replacement therapy attenuates retinal disease progression in a canine model of neuronal ceroid lipofuscinosis type 2 (CLN2)
    Sinclair, John
    Whiting, Rebecca
    Robinson, Grace
    Bibi, Katherin
    Nguyen, Annalisa
    Cherukuri, Anu
    Henshaw, Joshua
    de Hart, Gregory
    Sundeep, Chandra
    O'Neil, Chuck
    Katz, Martin
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [26] An essential function of Grr1 for the degradation of Cln2 is to act as a binding core that links Cln2 to Skp1
    Kishi, T
    Yamao, F
    JOURNAL OF CELL SCIENCE, 1998, 111 : 3655 - 3661
  • [27] Structure-function analysis of the Saccharomyces cerevisiae G(1) cyclin Cln2
    Huang, KN
    Odinsky, SA
    Cross, FR
    MOLECULAR AND CELLULAR BIOLOGY, 1997, 17 (08) : 4654 - 4666
  • [28] Intracerebroventricular gene therapy that delays neurological disease progression is associated with selective preservation of retinal ganglion cells in a canine model of CLN2 disease
    Whiting, Rebecca E. H.
    Jensen, Cheryl A.
    Pearce, Jacqueline W.
    Gillespie, Lauren E.
    Bristow, Daniel E.
    Katz, Martin L.
    EXPERIMENTAL EYE RESEARCH, 2016, 146 : 276 - 282
  • [29] Neuronal ceroid lipofuscinosis genes, CLN2, CLN3 and CLN5 are spatially and temporally co-expressed in a developing mouse brain
    Fabritius, A. -L.
    Vesa, J.
    Minye, H. M.
    Nakano, I.
    Kornblum, H.
    Peltonen, L.
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2014, 97 (03) : 484 - 491
  • [30] Intrafamilial variability in late-onset CLN2 disease
    Goobie, Sharan
    Bujold, Jillian
    Dyack, Sarah
    MOLECULAR GENETICS AND METABOLISM, 2020, 129 (02) : S66 - S67